| Radiation and PD-(L) 1 treatment combinations: immune response and dose optimization via a predictive systems model Y Kosinsky, SJ Dovedi, K Peskov, V Voronova, L Chu, H Tomkinson, ... Journal for immunotherapy of cancer 6, 1-15, 2018 | 91 | 2018 |
| Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data KM Hallow, PJ Greasley, G Helmlinger, L Chu, HJ Heerspink, DW Boulton American Journal of Physiology-Renal Physiology 315 (5), F1295-F1306, 2018 | 58 | 2018 |
| Quantitative systems pharmacology: an exemplar model‐building workflow with applications in cardiovascular, metabolic, and oncology drug development G Helmlinger, V Sokolov, K Peskov, KM Hallow, Y Kosinsky, V Voronova, ... CPT: pharmacometrics & systems pharmacology 8 (6), 380-395, 2019 | 47 | 2019 |
| Chimeric antigen receptor T cell therapies: a review of cellular kinetic‐pharmacodynamic modeling approaches A Chaudhury, X Zhu, L Chu, A Goliaei, CH June, JD Kearns, AM Stein The Journal of Clinical Pharmacology 60, S147-S159, 2020 | 37 | 2020 |
| Quantitative mechanistic modeling in support of pharmacological therapeutics development in immuno-oncology K Peskov, I Azarov, L Chu, V Voronova, Y Kosinsky, G Helmlinger Frontiers in immunology 10, 450826, 2019 | 34 | 2019 |
| Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 … T Yakovleva, V Sokolov, L Chu, W Tang, PJ Greasley, H Peilot Sjögren, ... Diabetes, Obesity and Metabolism 21 (12), 2684-2693, 2019 | 32 | 2019 |
| Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis B Shulgin, Y Kosinsky, A Omelchenko, L Chu, G Mugundu, S Aksenov, ... Oncoimmunology 9 (1), 1748982, 2020 | 30 | 2020 |
| Differentiating the sodium‐glucose cotransporter 1 inhibition capacity of canagliflozin vs. dapagliflozin and empagliflozin using quantitative systems pharmacology modeling V Sokolov, T Yakovleva, L Chu, W Tang, PJ Greasley, S Johansson, ... CPT: Pharmacometrics & Systems Pharmacology 9 (4), 222-229, 2020 | 29 | 2020 |
| Modeling Na+-Ca2+ exchange in the heart: Allosteric activation, spatial localization, sparks and excitation-contraction coupling L Chu, JL Greenstein, RL Winslow Journal of molecular and cellular cardiology 99, 174-187, 2016 | 29 | 2016 |
| Drug-disease modeling in the pharmaceutical industry-where mechanistic systems pharmacology and statistical pharmacometrics meet G Helmlinger, N Al-Huniti, S Aksenov, K Peskov, KM Hallow, L Chu, ... European Journal of Pharmaceutical Sciences 109, S39-S46, 2017 | 26 | 2017 |
| Evaluation of Combination Strategies for the A2AR Inhibitor AZD4635 Across Tumor Microenvironment Conditions via a Systems Pharmacology Model V Voronova, K Peskov, Y Kosinsky, G Helmlinger, L Chu, A Borodovsky, ... Frontiers in Immunology 12, 617316, 2021 | 10 | 2021 |
| Na+ microdomains and sparks: Role in cardiac excitation-contraction coupling and arrhythmias in ankyrin-B deficiency L Chu, JL Greenstein, RL Winslow Journal of molecular and cellular cardiology 128, 145-157, 2019 | 10 | 2019 |
| Linking tumor microenvironment properties in murine syngeneic tumors with resistance to immune checkpoint inhibitors: Insights from a quantitative systems approach G Helmlinger, I Azarov, Y Kosinsky, V Voronova, L Chu, S Mosely, ... Cancer Research 79 (13_Supplement), 1082-1082, 2019 | 2 | 2019 |
| Quantitative modeling as a systematic approach for drug combination evaluation in immuno-oncology (IO) G Helmlinger, Y Kosinsky, L Chu, K Peskov, V Voronova, A Borodovsky, ... Cancer Research 78 (13_Supplement), 2098-2098, 2018 | 2 | 2018 |
| Potassium homeostasis and therapeutic intervention with sodium zirconium cyclosilicate: A model‐informed drug development case study LE Clegg, L Chu, M Nagard, DW Boulton, RC Penland CPT: Pharmacometrics & Systems Pharmacology 13 (2), 296-307, 2024 | 1 | 2024 |
| Comparison of different approaches to modeling early tumor size dynamics for accurate prediction of survival in non-small cell lung cancer (NSCLC) clinical trials Y Kosinsky, I Azarov, L Chu, G Helmlinger, K Peskov, S Aksenov JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 45, S123-S123, 2018 | 1 | 2018 |
| CONTRIBUTION AND REGULATION OF SGLT1 AND SGLT2 IN HEALTHY AND TYPE 2 DIABETES SUBJECTS: A DRUG-DISEASE MODELING STUDY. T Yakovleva, V Sokolov, L Chu, RC Penland, W Tang, PJ Greasley, ... CLINICAL PHARMACOLOGY & THERAPEUTICS 103, S51-S51, 2018 | 1 | 2018 |
| Model-based meta-analysis of glucosuria-related adverse events in SGLT2 inhibitors L Chu, RC Penland, G Helmlinger, DW Boulton J. Pharmacokinet Pharmacodyn 44, S92, 2017 | 1 | 2017 |
| Model-based meta-analysis of safety for immune checkpoint inhibitor combinations and monotherapy. K Abdallah, B Shulgin, K Peskov, Y Kosinsky, A Vergara-Silva, ... Journal of Clinical Oncology 35 (7_suppl), 89-89, 2017 | 1 | 2017 |
| Modeling the Role of NCX in the Regulation of Cardiomyocyte Microdomain Ca2+ Dynamics L Chu, JL Greenstein, RL Winslow Biophysical Journal 110 (3), 99a, 2016 | 1 | 2016 |
